Scalable Perfusion-Single-Use-Bioreactor’s – series 31
CellRetention™ P-SUB cultivate mammalian cell’s in suspension at high cell density via cell retention and perfusion mode operation for weeks. The customizable Perfusion-Single-Use-Bioreactor (P-SUB) with the SepraPor® Hollow-Fiber-Filter (HFF) and the high precision Thalia Alternating-Single-Use-Pump (A-SUP) concept and Single-Use-Sensor’s (SUS).
Solve common fouling problem and flush easily out debris inside the HFF lumens





CellRetention Perfusion-SUB photos sizes fully pre-assembled with SepraPor® Hollow-Fiber-Filter (HFF) and the Thalia diaphragm Single-Use-Pump (SUP) driving the perfusion process. The solution is the Pulsating-Tangential-Flow (PTF) driven by the unique Clotho or Lachesis or Atropos Drive Units.
Customizable CellRetention series 31 integrated portfolio:
- 80 - 150 ml P-SUB Working Volume (WV) - 250 ml VV - for Modular
- 80 - 200 ml P-SUB Working Volume (WV) - 300 ml VV - for DASbox
- 100 - 400 ml P-SUB Working Volume (WV) - 500 ml VV - for Cronus-PCS or most PCS
- 500 - 1.5 liter P-SUB Working Volume (WV) - 2.0 liter VV - for Cronus-PCS or most PCS
- 1 - 2 liter P-SUB Working Volume (WV) - 3.2 liter VV - for Cronus-PCS or most PCS
- 2 - 10 liter P-SUB Working Volume (WV) - 13 liter VV - for Cronus-PCS or most PCS
- 4 - 25 liter P-SUB Working Volume (WV) - 30 liter VV - 2026 - for Cronus-PCS
SUB, SUP, HFF integrated into one unit, pre-assembled with SUS, pre-packed and E-beam irradiated, all single-use (of course) and ready for easy use. Work with most Process-Control-Systems (PCS) combined with Clotho, Lachesis or Atropos Drive Unit manufactured by sister company www.cronus-pcs.com
Thalia diaphragm pump TM200 and TM300 combined with SepraPor® HFF series 500 and 700 for Process Intensification
- 50 - 500 liter foil bag Single-Use-Bioreactor + Thalia diaphragm pump + SepraPor HFF - ultimo 2026
Patents granted for CellMembra™, CerPhragm™, CellRetention™. SUBmerged™ patent applied for. Patents which gives PerfuseCell Freedom-to-Operate and eliminate infringement of others IPR.
